Investors working at the intersection of development and commercialization.

Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.

Our diversified portfolio of royalty assets generates consistent and predictable revenue streams for our shareholders. It includes treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten lifespan and quality of life for billions of people. We also maintain and license our CaptisolĀ® technology platform with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world.

The Ligand Advantage

Focus

We invest in late-stage assets and leverage our technology platform to generate royalties and revenues for our shareholders.

People

We are highly skilled investment professionals with deep scientific, clinical and regulatory expertise.

Approach

We aggregate diverse royalty assets into a single portfolio to reduce the binary risk that comes with investing in a single drug candidate.

By the Numbers

35

Ligand
employees

85+

portfolio
assets

4

investment
strategies

$10M-$40M

target investment
per product

All figures as of November 30, 2023, unless otherwise indicated.